$254 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 22 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | PDL BIOPHARMA INCnote 2.875% 2/15/15 | $43,580,000 | – | 30,974,000 | +100.0% | 17.17% | – | |
| New | MANNKIND CORPnote 3.750% 12/15/13 | $33,632,000 | – | 34,144,000 | +100.0% | 13.25% | – | |
| New | OPKO HEALTH INCnote 3.0% 2/1/33 | $30,795,000 | – | 29,500,000 | +100.0% | 12.13% | – | |
| New | PACIRA PHARMACEUTICALS INCnote 3.25% 2/1/19 | $25,756,000 | – | 18,500,000 | +100.0% | 10.15% | – | |
| SLXP | New | SALIX PHARMACEUTICALS INC | $19,845,000 | – | 300,000 | +100.0% | 7.82% | – |
| New | DENDREON CORPnote 2.875% 1/15/16 | $19,091,000 | – | 26,515,000 | +100.0% | 7.52% | – | |
| New | INTERMUNE INCnote 2.50% 9/15/18 | $14,068,000 | – | 17,000,000 | +100.0% | 5.54% | – | |
| NKTR | New | NEKTAR THERAPEUTICS | $10,523,000 | – | 911,053 | +100.0% | 4.15% | – |
| DEPO | New | DEPOMED INC | $10,354,000 | – | 1,842,280 | +100.0% | 4.08% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $10,161,000 | – | 182,300 | +100.0% | 4.00% | – |
| OGXI | New | ONCOGENEX PHARMACEUTICALS INC | $9,144,000 | – | 933,100 | +100.0% | 3.60% | – |
| MNKD | New | MANNKIND CORP | $7,707,000 | – | 1,184,784 | +100.0% | 3.04% | – |
| ECYT | New | ENDOCYTE INC | $6,115,000 | – | 465,763 | +100.0% | 2.41% | – |
| New | SAVIENT PHARMACEUTICALS INCnote 4.750% 2/1/18 | $4,571,000 | – | 30,476,000 | +100.0% | 1.80% | – | |
| New | CORSICANTO LTDnote 3.50% 1/15/32 | $2,722,000 | – | 2,500,000 | +100.0% | 1.07% | – | |
| NAVB | New | NAVIDEA BIOPHARMACEUTICALS INC | $2,318,000 | – | 868,079 | +100.0% | 0.91% | – |
| RMTI | New | ROCKWELL MEDICAL INC | $1,618,000 | – | 448,146 | +100.0% | 0.64% | – |
| New | SUPERNUS PHARMACEUTICALS INCnote 7.5% 5/1/19 | $1,253,000 | – | 10,000,000 | +100.0% | 0.49% | – | |
| DNDNQ | New | DENDREON CORP | $328,000 | – | 79,600 | +100.0% | 0.13% | – |
| CYCC | New | CYCLACEL PHARMACEUTICALS INC | $218,000 | – | 73,895 | +100.0% | 0.09% | – |
| AMBI | New | AMBIT BIOSCIENCES CORP | $0 | – | 46 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.